贝伐珠单抗联合化疗治疗铂类药敏感型复发性卵巢癌的效果和安全性分析  

Efficacy and Safety Analysis of Bevacizumab Combined with Chemotherapy in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer

作　　者：胡勤龙 Hu Qinlong(First Department of Medical Oncology,Xuzhou Peixian County People's Hospital,Xuzhou 221600,Jiangsu Province,China)

机构地区：[1]徐州市沛县人民医院肿瘤内一科,江苏徐州221600

出　　处：《中外医药研究》2024年第29期9-11,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探讨贝伐珠单抗联合化疗治疗铂类药敏感型复发性卵巢癌的临床效果和安全性。方法:选取2020年6月—2023年12月徐州市沛县人民医院收治的铂类药敏感型复发性卵巢癌患者78例为研究对象,采用随机数字表法分为对照组与观察组,各39例。对照组接受紫杉醇和卡铂治疗,观察组在对照组基础上联合贝伐珠单抗治疗。对比两组肿瘤标志物水平、临床疗效及不良反应发生情况。结果:治疗后,两组癌胚抗原、糖类抗原125、糖类抗原724水平均下降,观察组低于对照组(P<0.05);观察组客观缓解率、疾病控制率均高于对照组(P<0.05);两组恶心呕吐、肝肾功能异常、骨髓抑制、高血压、白细胞减少、神经毒性不良反应发生率对比,差异均无统计学意义(P>0.05)。结论:给予铂类药敏感型复发性卵巢癌患者贝伐珠单抗联合化疗,能够有效改善患者的血清肿瘤标志物水平,提高客观缓解率和疾病控制率,且不会增加不良反应发生率,用药安全性较高。Objective:To investigate the clinical efficacy and safety of bevacizumab combined with chemotherapy in the treatment of platinum drug sensitive recurrent ovarian cancer.Methods:A total of seventy-eight patients with platinum drug-sensitive recurrent ovarian cancer treated in Xuzhou Peixian County People's Hospital from June 2020 to December 2023 were selected as the study objects,and were divided into control group and observation group by random number table method,with thirty-nine cases in each group.The control group was treated with paclitaxel and carboplatin,and the observation group was treated with bevacizumab based on the control group.The level of tumor markers,clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,the levels of carcinoembryonic antigen,carbohydrate antigen 125 and carbohydrate antigen 724 were decreased in both groups,and the observation group was lower than the control group(P<0.05);the objective remission rate and disease control rate of observation group were higher than those of control group(P<0.05);there were no significant differences in the incidence of nausea and vomiting,abnormal liver and kidney function,bone marrow depression,hypertension,leukopenia and neurotoxic adverse reactions between the two groups(P>0.05).Conclusion:The administration of bevacizumab combined with chemotherapy in patients with platinum drug-sensitive recurrent ovarian cancer can effectively improve the level of serum tumor markers,improve the objective response rate and disease control rate,and does not increase the incidence of adverse reactions,and has high drug safety.

关 键 词：贝伐珠单抗 化疗 卵巢癌 铂类药敏感 安全性 

分 类 号：R737.31[医药卫生—肿瘤]